Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies

• Published in: Journal of clinical oncology Vol. 41; no. 6_suppl; p. 241
• Main Authors: Weiner, Adam B, Liu, Yang, Hakansson, Alexander K., Zhao, Xin, Proudfoot, James Alexander, Zhang, JJ Haijing, Karnes, R. Jeffrey, Den, Robert Benjamin, Kishan, Amar Upadhyaya, Reiter, Robert Evan, Hamid, Anis, Ross, Ashley, Tran, Phuoc T., Chua, Melvin L.K. Lee Kiang, Spratt, Daniel Eidelberg, Attard, Gerhardt, Lotan, Tamara L., Sweeney, Christopher J, Davicioni, Elai, Schaeffer, Edward M.
• Format: Journal Article
• Language: English
• Published: 20.02.2023
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2023.41.6_suppl.241

241 Background: We previously reported on the use of gene expression profiling to characterize four primary subtypes in an analysis of over 100,000 prostate cancer primary tumors. Here we examine these subtypes and response to radiation (RT) after prostatectomy or chemotherapy in addition to androgen deprivation therapy (ADT) in hormone-sensitive metastatic prostate cancer (mHSPC). Methods: We examined a 215-gene prostate subtyping classifier (PSC) which groups luminal and basal gene expression profiles into one of four subtypes; luminal differentiated (LD), luminal proliferating (LP), basal immune (BI) and basal neuroendocrine-like (BN). The log-rank method was used to compare (i) metastasis-free survival between patients who did and did not receive salvage RT in the META855 cohort of localized disease patients treated with radical prostatectomy (n=855) and the (ii) overall survival of patients on the Phase III mHSPC EA3805 CHAARTED trial of ADT or ADT + docetaxel chemotherapy (n=160). Results: After radical prostatectomy, patients with BI tumors derived benefit from RT in terms of metastasis-free survival ( P=9.23e-4) while those with other subtype tumors did not (Each Log-rank P≥0.5). Patients with metastatic disease and LP tumors derived benefit from docetaxel (Log-rank P=0.002) while those with other subtypes tumors did not (Log-rank P=0.2). Conclusions: Basal-luminal subtyping segments tumors by relevant biological processes with potential implications for identifying patients who benefit from salvage radiation post prostatectomy and addition of docetaxel to ADT in mHSPC.